Establishment and validation of imatinib mesylate in plasma by liquid chromatography tandem mass spectrometry

Objective To establish a liquid chromatography tandem mass spectrometry (LC-MS/MS) for the quantitation determination of plasma imatinib mesylate and perform the general method Validation. Methods After proteins in plasma were precipitated, imatinib was analyzed by LC-MS/MS mode and multiple reaction monitor (MRM) mode, the ion pairs monitored were m/z 494.3→m/z 394.2 (imatinib), m/z237.3→m/z194.1 (carbamazepine, internal standard). Results The linear range was 6.25 to 3 200.00 μg/L. The within-run precision was 1.98%-4.46%, and between-run precision was 3.07%-7.54%. The correctness biaswas-7.34%-2.28%. Matrix effect factor was 0.93-1.05. Conclusion The method established is sensitive, accurate and stable, satisfying the quantification requirements of imatinib mesylate in plasma, and it could be used in clinical analysis. Key words: Imatinib mesylate; Liquid chromatography tandem mass spectrometry; Method validation